CannaPharmaRX, Inc.
CPMD
$0.00
$0.002.70%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -71.25% | 110.31% | -- | 1,199.61% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -71.25% | 110.31% | -- | 1,199.61% | -- |
| Cost of Revenue | -55.67% | 64.09% | 397.55% | 12.88% | 3,212.50% |
| Gross Profit | 51.23% | -23.53% | -262.43% | 29.85% | -2,477.59% |
| SG&A Expenses | 190.90% | 210.14% | -41.81% | -49.92% | 90.22% |
| Depreciation & Amortization | -- | -- | -- | -- | 9.16% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -48.65% | 92.28% | 96.41% | -8.41% | 384.90% |
| Operating Income | 41.51% | -81.32% | -51.68% | 37.56% | -316.57% |
| Income Before Tax | -101.82% | -884.39% | -126.36% | 94.11% | -149.58% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -101.82% | -884.39% | -126.36% | 94.11% | -149.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -101.82% | -884.39% | -126.36% | 94.11% | -149.58% |
| EBIT | 41.51% | -81.32% | -51.68% | 37.56% | -316.57% |
| EBITDA | -- | -- | -73.15% | 36.18% | -279.77% |
| EPS Basic | -103.57% | -833.33% | -125.93% | 97.01% | -126.54% |
| Normalized Basic EPS | 17.14% | -800.00% | -120.31% | 96.83% | -975.00% |
| EPS Diluted | -103.57% | -833.33% | -125.93% | 97.01% | -126.54% |
| Normalized Diluted EPS | 17.14% | -800.00% | -120.31% | 96.83% | -975.00% |
| Average Basic Shares Outstanding | -0.04% | 0.00% | 0.69% | 89.01% | 85.27% |
| Average Diluted Shares Outstanding | -0.04% | 0.00% | 0.69% | 89.01% | 85.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |